Explore
Trendline
NanoViricides Reports Q3 FY2026 Financial Results, Advances Clinical Trials
NanoViricides Reports Q3 FY2026 Financial Results, Advances Clinical Trials
Read More
Trendline
Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements
Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements
Read More
Trendline
Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026
Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026
Read More
Trendline
Atara Biotherapeutics Reports First Quarter 2026 Financial Results Highlighting Operational Progress
Atara Biotherapeutics Reports First Quarter 2026 Financial Results Highlighting Operational Progress
Read More
Trendline
Edesa Biotech Reports Increased Net Loss Amid R and Manufacturing Expansion
Edesa Biotech Reports Increased Net Loss Amid R and Manufacturing Expansion
Read More
Trendline
Spruce Biosciences Reports Q1 2026 Financial Results and Corporate Updates
Spruce Biosciences Reports Q1 2026 Financial Results and Corporate Updates
Read More
Trendline
Inhibrx Reports First Quarter 2026 Financial Results Highlighting Clinical Progress
Inhibrx Reports First Quarter 2026 Financial Results Highlighting Clinical Progress
Read More
Trendline
Immunome Submits NDA for Varegacestat and Reports Financial Results
Immunome Submits NDA for Varegacestat and Reports Financial Results
Read More
Trendline
INOVIO Announces First Quarter 2026 Financial Results and Advances in DNA Medicine Development
INOVIO Announces First Quarter 2026 Financial Results and Advances in DNA Medicine Development
Read More
Trendline
Inhibrx Reports Financial Results and Clinical Trial Updates for Q1 2026
Inhibrx Reports Financial Results and Clinical Trial Updates for Q1 2026
Read More
Trendline
PepGen Reports Financial Results and Advances in Neuromuscular Therapy Trials
PepGen Reports Financial Results and Advances in Neuromuscular Therapy Trials
Read More
Trendline
Imunon, Inc. Reports Increased Net Loss in Q1 2026 Amid Clinical Advancements
Imunon, Inc. Reports Increased Net Loss in Q1 2026 Amid Clinical Advancements
Read More
